Defense Medical Research and Development Program Clinical Trial Award - Regenerative Medicine, Pain, Sensory System

archived

The DMRDP Clinical Trial Award-Regenerative Medicine, Pain, Sensory System (CTA-RPS) is intended to support early phase clinical trials with the potential to have a major impact on treatment of combat-related injuries in the areas of pain, restoration of sensory systems (balance, hearing, and vision), and regenerative medicine technologies. All studies must be responsive to the health care needs of military service members and veterans, and all applications must specifically and clearly address the military relevance of the proposed research; however, the use of military populations in the clinical trial is not a requirement. Proposed projects should be designed to demonstrate the safety and efficacy of novel therapies and diagnostics in human patients suffering from serious, debilitating injuries of the extremities, skin, sensory systems, or craniomaxillofacial area due to trauma. The purpose of such demonstrations is to accelerate translation of greater medical capabilities to patients; this can range from proof of concept (i.e. first in human or Phase 0) trials through Phase II clinical trials, as well as Class I, II, or III device trials. Phase III clinical trials are not allowed. Projects of interest are those focused on testing and translating investigational interventions already proven in relevant definitive animal models, moving them into advanced clinical development. Funding from this award mechanism must support a clinical trial and cannot be used for preclinical research studies.

High